FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPR	OVAL				
OMB Number:	3235-0104				
Estimated average burden					
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Mostafa Adam S.	2. Date of Event Requiring Statem (Month/Day/Year) 03/13/2019	nent 5	3. Issuer Name <b>and</b> Ticker or Trading Symbol X4 Pharmaceuticals, Inc [ XFOR ]							
(Last) (First) (Middle) C/O X4 PHARMACEUTICALS, INC.			I. Relationship of Reporting Perso Check all applicable) Director	10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year)				
955 MASSACHUSETTS AVENUE, 4TH FLOOR			X Officer (give title below)  See Remark			6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person				
(Street) CAMBRIDGE MA						Form filed b Reporting P	by More than One Person			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
	Table I - Non	-Derivativ	ve Securities Beneficial	y Owned						
1. Title of Security (Instr. 4)	Table I - Non	2. /	ve Securities Beneficiall Amount of Securities eneficially Owned (Instr. 4)	y Owned  3. Ownersh Form: Direct or Indirect (Instr. 5)	cṫ (D)   (Ins	ature of Indirect tr. 5)	Beneficial Ownership			
	Table II - D	2. A Be	Amount of Securities	3. Ownersh Form: Direct or Indirect (Instr. 5)	et (D) (Ins		Beneficial Ownership			
	Table II - D	erivative s, warran	Amount of Securities eneficially Owned (Instr. 4)  Securities Beneficially	3. Ownersh Form: Direct or Indirect (Instr. 5) Owned securitie	et (D) (Ins	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)			

**Explanation of Responses:** 

Chief Financial Officer and Treasurer Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

/s/ Adam S. Mostafa 03/14/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

Know all by these present, that the undersigned hereby constitutes and appoints each of Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals, Inc. (the "Company"), Adam S. Mostafa, Chief Financial Officer of the Company, and Daniel T. Kajunski, John P. Condon, Christina S. Bailey, Amanda Mei, Brenda L. Meyette and Anne T. Leland of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 7th day of March, 2019.